Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy - Wikidata - wikimedia - TriplyDB

Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy

Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy

http://www.wikidata.org/entity/Q33705718

about

Pharmacology of Corticosteroids for Diabetic Macular Edema.Efficacy and safety of fluocinolone acetonide 0.025% otic solution in patients with otic eczema: a randomized, double-blind, placebo-controlled clinical trial

P2860

Q47753853-9D649222-D58E-4A57-8D6A-DC2CD4A31690 Q58703619-D80EEBDD-77FB-48C0-9100-3FA82B10BAA9

P2860

Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy

http://www.wikidata.org/entity/Q33705718

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Efficacy of 0.2 μg/day fluocin ...... lar edema and prior vitrectomy

@ast

Efficacy of 0.2 μg/day fluocin ...... lar edema and prior vitrectomy

@en

type

label

Efficacy of 0.2 μg/day fluocin ...... lar edema and prior vitrectomy

@ast

Efficacy of 0.2 μg/day fluocin ...... lar edema and prior vitrectomy

@en

prefLabel

Efficacy of 0.2 μg/day fluocin ...... lar edema and prior vitrectomy

@ast

Efficacy of 0.2 μg/day fluocin ...... lar edema and prior vitrectomy

@en

P1433

Q33705718-C1F485FF-4842-42EA-8EB1-792C3AA5F90A

P1476

Q33705718-747036ED-E8AB-4AE6-922E-76B596E3144A

P2093

Q33705718-38FA067F-4FBD-4CF6-B934-ACD9597B671A

Q33705718-585494B1-56E4-41C0-8A86-2B7DE7665EC0

Q33705718-A0A12E0A-DD57-4B1F-AAD7-1CC35E42A4BB

Q33705718-A550737D-C7CD-4536-9A8B-5FEC5175DE78

Q33705718-A6CC9508-C9CE-4065-BA16-8C819A190B57

Q33705718-AF220877-6031-42BA-8F59-CAD692C4579D

Q33705718-C0257894-19DA-40AC-B399-3B6C02AAD2D2

Q33705718-D0B31BAF-A125-46FF-B6FD-7AB7B145BCFC

Q33705718-D76340F6-28AC-4D92-B915-2202DAC2536E

Q33705718-FDCE8DC4-F3F6-4F59-8745-1579DC83EBF8

P2860

Q33705718-0EA33FFD-5E89-4B40-B9D4-AFBB270B7AF1

Q33705718-1BF5A903-81E7-4E9C-A5E4-A7796EE9E176

Q33705718-1F67796A-CFDC-4FA6-8D56-818F9E16CE7F

Q33705718-23AC0278-F35E-48B0-8E9E-299EF66DE592

Q33705718-2CF4E105-61D3-4691-9850-2459C860B8AB

Q33705718-3D0E355D-E95D-4467-B095-C7757A20D7CA

Q33705718-4661686C-21B8-4F28-B814-E28026BC4C6F

Q33705718-4A8D11A2-1797-467B-9BB4-795643CC009C

Q33705718-4FF358EA-20F7-4804-ADB8-64779C1204CF

Q33705718-51E127B5-25E0-43EE-BB8E-E5A3B19FBFDF

P2888

Q33705718-A405603B-B0CC-4D68-BCAC-2AB38EDD9B75

P304

Q33705718-20CB652A-F34F-4F06-8B6C-8F58DA3F682D

P31

Q33705718-ADB3CB01-BF4C-490E-9291-B6ABA2D0F304

P356

Q33705718-35C7C721-A308-4D62-9E9C-EB1990CF7D3F

P433

Q33705718-B5F18084-83B0-4787-AF50-F5C52BB5B861

P478

Q33705718-DAD75D2B-5F2B-428B-952E-56B1EC74C47F

P50

Q33705718-1C95B75E-5E0E-47D8-AC13-E6503420A0FF

Q33705718-A5980A68-FB37-4C79-B3A5-A92E0739ACA7

P577

Q33705718-88F86B19-36AA-4B92-B9AF-9526224E3A2E

P6179

Q33705718-B0F0B522-3C36-45BD-AC73-1A6D0E3F8AC5

P698

Q33705718-44119AEE-D59F-4E28-AF84-272A648714E3

P932

Q33705718-CA5D16EC-A753-4637-9F99-6E349A59EBC8

P356

P1433

P1476

Efficacy of 0.2 μg/day fluocin ...... lar edema and prior vitrectomy

@en

P2093

A Erginay

http://www.w3.org/2001/XMLSchema#string

A Meireles

http://www.w3.org/2001/XMLSchema#string

B Pessoa

http://www.w3.org/2001/XMLSchema#string

C Goldsmith

http://www.w3.org/2001/XMLSchema#string

I El-Ghrably

http://www.w3.org/2001/XMLSchema#string

J Atorf

http://www.w3.org/2001/XMLSchema#string

M Habib

http://www.w3.org/2001/XMLSchema#string

P Massin

http://www.w3.org/2001/XMLSchema#string

R Tadayoni

http://www.w3.org/2001/XMLSchema#string

T Patel

http://www.w3.org/2001/XMLSchema#string

P2860

A Novel Technique for Repositioning of a Migrated ILUVIEN(®) (Fluocinolone Acetonide) Implant into the Anterior Chamber.

Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data.

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.

Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema.

Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema.

Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets.

RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.

A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study).

Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting

P2888

P304

684-690

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/EYE.2016.303

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Prof. Dr. Albert J. Augustin

P577

2017-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1041558444

http://www.w3.org/2001/XMLSchema#string

P698

28085139

http://www.w3.org/2001/XMLSchema#string

P932

5437318

http://www.w3.org/2001/XMLSchema#string